רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה) ישראל - עברית - Ministry of Health

רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה)

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - suspension - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, and g4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rorateq should be administered betwen 6 and 12 weeks of age.

רוטריקס תרחיף ישראל - עברית - Ministry of Health

רוטריקס תרחיף

glaxo smith kline (israel) ltd - live attenuated human rotavirus rix4414 strain - תרחיף - live attenuated human rotavirus rix4414 strain - rota virus, live attenuated - rota virus, live attenuated - rotarix is indicated for the active immunization of infants from the age of 6 weeks for prevention of gastro-enteritis due to rotavirus infection. in clinical trials, efficacy was demonstrated against gastro-enteritis due to rotavirus of types g1p[8], g2p[4], g3p[8], g4p[8] and g9p[8]. the use of rotarix should be based on official recommendations.